Business Context and Reporting Period
Company: BioTime, Inc. (Note: Metadata referenced Lineage Cell Therapeutics, but filing is for BioTime, Inc.)
Reporting Period: Quarterly period ended March 31, 1998 (Nine months ended March 31, 1998).
Status: Development stage company engaged in R&D of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions.
Key Milestone: Submitted New Drug Application (NDA) to the FDA for Hextend on March 31, 1998.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1998 | Nine Months Ended Mar 31, 1998 | Cumulative (Inception to Mar 31, 1998) |
|---|---|---|---|
| Revenue | $125,000 | $775,000 | $837,500 |
| Net Loss | $(1,071,538) | $(2,691,336) | $(13,850,017) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.27) | $(2.01) |
| Cash and Equivalents (Ending) | $5,145,634 | ||
| Net Cash Used in Operating Activities | $(3,406,985) (Nine Months) | ||
| Total Assets | $5,584,691 | ||
| Total Liabilities | $831,491 |
Material Changes vs. Prior Period
- Revenue: Increased from $0 in the prior year quarter to $125,000, driven by the amortization of deferred license fees from the Abbott Laboratories agreement.
- Operating Expenses:
- R&D: Increased 124% year-over-year for the three-month period ($878,422 vs. $392,237) due to Phase III clinical trial completion and NDA preparation.
- G&A: Increased 124% year-over-year for the three-month period ($390,904 vs. $174,673) due to increased personnel costs.
- Liquidity: Cash balance decreased by approximately $2.67 million during the nine-month period, primarily due to operating losses and equipment purchases.
Outlook, Risks, and Management Commentary
- Licensing Agreement: Exclusive license with Abbott Laboratories for Hextend in the U.S. and Canada. Abbott has paid $1.4 million to date; $250,000 was received in May 1998 (post-period) for NDA submission. Up to $40 million in potential fees and royalties remain.
- Regulatory Status: NDA submitted for Hextend. FDA approval is not guaranteed. Company is pursuing global licensing and potential clinical trials in Europe and Japan.
- Capital Needs: Management expects continued losses and states that additional financing (equity, debt, or licensing) is required to complete product development and clinical trials.
- Risks: Dependence on FDA approval, ability to secure financing, competition, and the success of clinical trials. The company has no significant operating revenues outside of license fees.
Investor Verification Checklist
- FDA Approval Timeline: Verify the status of the Hextend NDA review and any FDA requests for additional data.
- Cash Runway: Assess if the $5.1 million cash balance is sufficient to fund operations until the next anticipated financing or revenue milestone.
- Abbott Milestones: Confirm the specific triggers for the remaining $38.6 million in potential license fees and the timeline for NDA approval.
- Global Licensing: Monitor progress on licensing discussions with international partners (e.g., Nihon Pharmaceutical) to diversify revenue streams.
- Dilution Risk: Review outstanding options and warrants (approx. 541,500 options and 825,000+ warrants) that could dilute existing shareholders upon exercise.